Eptifibatide is a peptide-based antagonist for glycoprotein IIb/IIIa used in the medical management of myocardial infarction and as an adjunct to percutaneous coronary intervention. Synthetic cyclic hexapeptide that binds to platelet receptor glycoprotein and inhibits platelet aggregation.
- Mechanism
- Curator reviewed
Eptifibatide inhibits platelet aggregation by reversibly binding to the platelet receptor glycoprotein (GP) IIb/IIIa of human platelets, thus preventing the binding of fibrinogen, von Willebrand factor, and other adhesive ligands. Inhibition of platelet aggregation occurs in a dose- and concentration-dependent manner.
- Primary indication
- For treatment of myocardial infarction and acute coronary syndrome.Curator reviewed · 2 structured indications
- Formula / weight
- C35H49N11O9S2 · 831.962 Da
- First approval
- Canada, 2011 · United States, 1998 · European Union, 2016
- Also known as
- Integrelin · Intrifiban
- Brand names
Resolves to
What you can answer from here — as of July 17, 2026
Which drugs share a target with Eptifibatide, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account